/AKRO
AKRO Stock - Akero Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$54.65+0.00%
+$0.00 (+0.00%) • Dec 9
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.73
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).50
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+0.0%upside
Target: $54.65
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AKRO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$54.10 – $55.20
TARGET (TP)$54.67
STOP LOSS$50.28
RISK/REWARD1:0.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.40
52W High$58.40
52W Low$21.34
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-213,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-285,423,000 | $-172,870,000 | $-115,156,000 | $-100,886,000 | $-80,154,000 |
| Net Income | $-252,060,000 | $-151,759,000 | $-112,033,000 | $-100,777,000 | $-79,190,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.75 | $-2.89 | $-2.87 | $-2.89 | $-2.52 |
Company Overview
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
88%
Hold / Neutral
1
13%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish1 Neutral/Bearish
Price Targets
$65
Average Target
↑ 18.0% Upside
Now
$30
Low
$65
Average
$83
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 4th 2025 | H.C. Wainwright | Resumed | Buy | $72 |
| August 4th 2025 | TD Cowen | Initiation | Buy | $76 |
| January 30th 2025 | BofA Securities | Upgrade | Buy | $63← $35 |
| January 27th 2025 | H.C. Wainwright | Reiterated | Buy | $72← $50 |
| November 18th 2024 | Citigroup | Initiation | Buy | $65 |
| April 22nd 2024 | BofA Securities | Resumed | Neutral | $30 |
| September 19th 2023 | Cantor Fitzgerald | Initiation | Overweight | $69 |
| August 28th 2023 | UBS | Initiation | Buy | $83 |
| January 27th 2023 | Morgan Stanley | Upgrade | Overweight | $65← $40 |
| September 14th 2022 | Evercore ISI | Upgrade | Outperform | $50← $10 |
Earnings History & Surprises
AKROBeat Rate
50%
Last 18 quarters
Avg Surprise
+11.4%
EPS vs Estimate
Beats / Misses
9/8
1 met exactly
Latest EPS
$-0.99
Q4 2025
EPS Surprise History
Q1 24
-20.7%
$-0.99vs$-0.82
Q2 24
0.0%
$-0.90vs$-0.90
Q3 24
+10.0%
$-0.81vs$-0.90
Q4 24
-16.7%
$-1.05vs$-0.90
Q1 25
-1.0%
$-0.99vs$-0.98
Q2 25
+189.1%
$0.90vs$-1.01
Q3 25
+11.3%
$-0.86vs$-0.97
Q4 25
-5.3%
$-0.99vs$-0.94
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $-1.00 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.94 | $-0.99 | -5.3% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $-0.97 | $-0.86 | +11.3% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-1.01 | $0.90 | +189.1% | ✓ BEAT |
Q1 2025 | Feb 28, 2025 | $-0.98 | $-0.99 | -1.0% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $-0.90 | $-1.05 | -16.7% | ✗ MISS |
Q3 2024 | Aug 9, 2024 | $-0.90 | $-0.81 | +10.0% | ✓ BEAT |
Q2 2024 | May 10, 2024 | $-0.90 | $-0.90 | 0.0% | = MET |
Q1 2024 | Feb 29, 2024 | $-0.82 | $-0.99 | -20.7% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.69 | $-0.71 | -2.9% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-0.62 | $-0.60 | +3.2% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.62 | $-0.55 | +11.3% | ✓ BEAT |
Q1 2023 | Mar 17, 2023 | $-0.78 | $-0.49 | +37.2% | ✓ BEAT |
Q4 2022 | Nov 4, 2022 | $-0.73 | $-0.92 | -26.0% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.85 | $-0.77 | +9.4% | ✓ BEAT |
Q2 2022 | May 6, 2022 | $-0.85 | $-0.74 | +12.9% | ✓ BEAT |
Q1 2022 | Feb 25, 2022 | $-0.81 | $-0.93 | -14.8% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.91 | $-0.70 | +23.1% | ✓ BEAT |
Q3 2021 | Aug 13, 2021 | $-0.72 | $-0.83 | -15.3% | ✗ MISS |
Latest News
Cantor Fitzgerald Suspends Overweight Rating on Akero Therapeutics
📉 NegativeBenzinga•Dec 10, 2025, 01:56 PM
Akero Therapeutics Shareholders Approved Proposed Takeover By Novo Nordisk
📈 PositiveBenzinga•Dec 3, 2025, 03:46 PM•Also:
Akero Therapeutics Highlights New Data Showing Liver Fibrosis Reversal in MASH Patients
📈 PositiveBenzinga•Nov 7, 2025, 12:07 PM
Wolfe Research Downgrades Akero Therapeutics to Peer Perform
📉 NegativeBenzinga•Oct 10, 2025, 11:27 AM
HC Wainwright & Co. Downgrades Akero Therapeutics to Neutral, Lowers Price Target to $54
📉 NegativeBenzinga•Oct 10, 2025, 10:56 AM
Akero Therapeutics Says If Deal Terminated Under Some Circumstances, Co To Pay $165M Termination Fee To Novo Nordisk
📉 NegativeBenzinga•Oct 9, 2025, 08:50 PM•Also:
Jefferies Downgrades Akero Therapeutics to Hold, Lowers Price Target to $56
📉 NegativeBenzinga•Oct 9, 2025, 04:15 PM
Canaccord Genuity Downgrades Akero Therapeutics to Hold, Lowers Price Target to $54
📉 NegativeBenzinga•Oct 9, 2025, 03:38 PM•Also:
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
📈 PositiveSeeking Alpha•Oct 9, 2025, 03:33 PM•Also: , ,
Akero Therapeutics shares are trading higher after the company announced it will be acquired by Novo Nordisk for up to $5.2 billion.
📈 PositiveBenzinga•Oct 9, 2025, 12:44 PM•Also:
Akero Therapeutics soars on $5.2 billion acquisition deal with Novo Nordisk
📈 PositiveSeeking Alpha•Oct 9, 2025, 10:07 AM•Also:
Novo Nordisk To Acquire Akero Therapeutics For $54/Share
📈 PositiveBenzinga•Oct 9, 2025, 10:03 AM•Also:
Akero Therapeutics To Present 96-Week Phase 2b SYMMETRY And HARMONY Data On Efruxifermin At 76th AASLD The Liver Meeting 2025
➖ NeutralBenzinga•Oct 7, 2025, 11:10 AM
HC Wainwright & Co. Assumes Akero Therapeutics at Buy, Announces Price Target of $72
📈 PositiveBenzinga•Sep 4, 2025, 11:14 AM
Akero surges after report on plans for potential sale
📈 PositiveSeeking Alpha•May 20, 2025, 05:41 PM
Frequently Asked Questions about AKRO
What is AKRO's current stock price?
Akero Therapeutics, Inc. (AKRO) is currently trading at $54.65 per share. The stock has moved +0.00% today.
What is the analyst price target for AKRO?
The average analyst price target for AKRO is $54.67, based on 1 analyst.
What sector is Akero Therapeutics, Inc. in?
Akero Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AKRO's market cap?
Akero Therapeutics, Inc. has a market capitalization of $4.50 billion, making it a mid-cap company.
Does AKRO pay dividends?
No, Akero Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
ACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
NAMS
NewAmsterdam Pharma Company N.V.
$35.11
Mkt Cap: $4.0B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
Explore stocks similar to AKRO for comparison